Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy

Journal of the Neurological Sciences

Volumn 216, Issue 1, 2003, Pages 99-103

  Govoni, Vittorio ^a   Granieri, Enrico ^a   Manconi, Mauro ^a   Capone, Jay ^a   Casetta, Ilaria ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Bovine gangliosides; Guillain Barr syndrome; Incidence; Temporal pattern

Indexed keywords

GANGLIOSIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY;

EID: 0242523139     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00215-6     Document Type: Article

References (35)

1. Hahn A.F. Guillain-Barré syndrome. Lancet. 352:1998;635-641.
2. Asbury A.K. New concepts of Guillain-Barré syndrome. J. Child Neurol. 15:2000;183-191.
3. Garattini S., Garattini L. Pharmaceutical prescriptions in four European countries. Lancet. 342:1993;1191-1192.
4. Schönhöfer P.S. Guillain-Barré syndrome and parenteral gangliosides. Lancet. 338:1991;757.
5. Figueras A., Morales-Olivas F.J., Capella D., Palop V., Laporte J.R. Bovine gangliosides and acute motor polyneuropathy. BMJ. 305:1992;1330-1331.
6. Landi G., D'Alessandro R., Currò Dossi B., Ricci S., Simone I.L., Ciccone A. Guillain-Barré syndrome after exogenous gangliosides in Italy. BMJ. 307:1993;1403-1404.
7. Behan P.O., Haniffah B.A.G. Gangliosides and neurological diseases. BMJ. 305:1992;1309-1310.
8. Keates T. Gangliosides in Italy. Lancet. 343:1994;108.
9. Latov N., Koski C.L., Walicke P.A. Guillain-Barré syndrome and parenteral gangliosides. Lancet. 338:1991;757.
10. Nobile-Orazio E., Carpo M., Meucci N., Grassi M.P., Capitani E., Sciacco M.et al. Guillain-Barré syndrome associated with high titres of anti-GM1 antibodies. J. Neurol. Sci. 109:1992;200-206.
11. Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M., Dalakas M.C. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 38:1995;218-224.
12. Gong Y., Tagawa Y., Lunn M.P.T., Laroy W., Heffer-Lauc M., Li C.Y.et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain. 125:2002;2491-2506.
13. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 125:2002;2591-2625.
14. Govoni V., Granieri E., Tola M.R., Paolino E., Casetta I., Fainardi E.et al. Exogenous gangliosides and Guillain-Barré syndrome. An observational study in the Local Health District of Ferrara, Italy. Brain. 120:1997;1123-1130.
15. Paolino E., Govoni V., Tola M.R., Casetta I., Granieri E. Incidence of the Guillain-Barré syndrome in Ferrara, northern Italy, 1981-1987. Neuroepidemiology. 10:1991;105-111.
16. Govoni V., Granieri E., Casetta I., Tola M.R., Paolino E., Fainardi E.et al. The incidence of Guillain-Barré syndrome in Ferrara, Italy: is the disease really increasing? J. Neurol. Sci. 137:1996;62-68.
17. Alter M. The epidemiology of Guillain-Barré syndrome. Ann. Neurol. 27(Suppl.):1990;S7-S12.
18. Govoni V., Granieri E. Epidemiology of Guillain-Barré syndrome. Curr. Opin. Neurol. 14:2001;605-613.
19. Granieri E., Casetta I., Govoni V., Tola M.R., Paolino E., Rocca W.A. Ganglioside therapy and Guillain-Barré syndrome. A historical cohort study in Ferrara, Italy, fails to demonstrate an association. Neuroepidemiology. 10:1991;161-169.
20. McDonald J.W., Sadowsky C. Spinal-cord injury. Lancet. 359:2002;417-425.
21. Geisler F.H., Coleman W.P., Grieco G., Poonian D. The Sygen Multicenter Acute Spinal Cord Injury Study. Spine. 26(Suppl. 24):2001;S87-S98.
22. Asbury A.K., Arnason B.G.W., Karp H.R., McFarlin D.E. Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 3:1978;565-566.
23. Schoenberg B.S. Calculating confidence intervals for rates and ratios: simplified method utilizing tabular values based on the Poisson distribution. Neuroepidemiology. 2:1983;257-265.
24. Waterhause J., Muir C., Shanmungaratham K., Powell J. Cancer incidence in five continents. IARC Sci. Publ. 4:1982;673.
25. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 11:1955;375-386.
26. Raschetti R., Maggini M., Popoli P., Caffari B., da Cas R., Menniti-Ippolito F.et al. Gangliosides and Guillain-Barré syndrome. J. Clin. Epidemiol. 48:1995;1399-1405.
27. Beghi E. Exposure to exogenous gangliosides and Guillain-Barré syndrome. Neuroepidemiology. 14:1995;45-48.
28. Risk factors for Guillain-Barré syndrome: a population-based case-control study. J. Neurol. 246:1999;1004-1009.
29. Odaka M., Yuki N., Nobile-Orazio E., Carpo M., Hirata K. Antibodies to GM1 (NeuGc) in Guillain-Barré syndrome after ganglioside therapy. J. Neurol. Sci. 175:2000;96-106.
30. Jiang G.-X., Cheng Q., Link H., de Pedro-Cuesta J. Epidemiological features of Guillain-Barré syndrome in Sweden, 1979-1993. J. Neurol. Neurosurg. Psychiatry. 62:1997;447-453.
31. Larsen J.P., Kvale G., Nyland H. Epidemiology of Guillain-Barré syndrome in the county of Hordaland, Western Norway. Acta Neurol. Scand. 71:1985;43-47.
32. Van Konigsveld R., Van Doorn P.A., Schmitz P.I.M., Ang C.W., van Der Meché F.G.A. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands. Neurology. 54:2000;620-625.
33. Cheng Q., Jiang G.-X., Fredrikson S., Link H., de Pedro-Cuesta J. Incidence of Guillain-Barré syndrome in Sweden 1996. Eur. J. Neurol. 7:2000;11-16.
34. Koobatian T.J., Birkhead G.S., Schramm M.M., Vogt R.L. The use of hospital data for public health surveillance of Guillain-Barré syndrome. Ann. Neurol. 30:1991;618-621.
35. A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology. 48:1997;214-221.